Global Scientific and Academic Research Journal of Multidisciplinary Studies
ISSN: 2583-4088 (Online)
Frequency: Monthly
Published By GSAR Publishers
Journal Homepage Link- https://gsarpublishers.com/journals-gsarjms-home/

Review on pain relief medicines

By

[1*]Ashvini Mansing Deshmukh, [2]Pratiksha Prasadrao Deshmukh, [3]Dr. Sunita Satish Sakure

[1*]Assistant Professor, Department of Chemistry, S. B. B. Alias Appasaheb Jedhe College, Pune
[2]Assistant Professor, Department of Chemistry, S. B. B. Alias Appasaheb Jedhe College, Pune
[3]Head, Department of Microbiology, S. B. B. Alias Appasaheb Jedhe College, Pune

Article History

Received: 15/08/2025
Accepted: 23/08/2025
Published: 25/08/2025

Vol – 4 Issue –8

PP: - 67-78

Abstract

Analgesics, often known as pain relievers, are a broad class of drugs designed to reduce various types of pain, thereby improving the quality of life for people suffering from a variety of medical illnesses. This page includes a detailed summary of the most often used analgesic classes, including as acetaminophen (paracetamol), opioids, and nonsteroidal anti-inflammatory medications (NSAID). Each class is examined in terms of its pharmacological mechanism of action, with a particular emphasis on interactions with pain receptors, brain pathways, and the control of inflammatory responses that influence pain perception. Acetaminophen, which is commonly used for mild to moderate pain, works primarily by blocking prostaglandin synthesis in the central nervous system. NSAIDs, such as ibuprofen and aspirin, decrease pain and inflammation by blocking the cyclooxygenase (COX) enzymes that produce prostaglandin. Opioids, such as morphine and oxycodone, operate directly on opioid receptors in the brain and spinal cord, making them useful for severe pain while raising concerns about tolerance, dependence, and addiction. The review also compares the efficacy of several analgesics for acute, chronic, and neuropathic pain, emphasising that no single medicine is universally good. The patient's age, underlying health issues, degree and nature of pain, dosage, and treatment length are all important considerations for deciding the best course of action. While these treatments give great comfort, they do not come without hazards. NSAIDs have been linked to gastrointestinal and cardiovascular problems, but opioids are highly addictive. As a result, there is increased interest in new medicines such as biologics, cannabinoids, and non-pharmacologic techniques, which hold promise for safer, more personalised pain management. The research emphasises the importance of individualised pain treatment techniques that balance efficacy and safety, incorporating medical history, risk assessment, and patient-centered goals to achieve best therapeutic outcomes.

Keywords: *Pain, Pain relief, Pain killer*

INTRODUCTION

Pain is a sensory and emotional experience causing harm, often caused by strong stimuli. Analgesics like NSAIDs and painkillers help relieve pain. Congenital insensitivity to pain (CIP) is a rare disease where a person cannot perceive physical pain. Xenon Pharmaceutical developed XEN402 to block voltage-dependent Na+ channels in chronic conditions. Pain is a self-preservation mechanism, but being painless can lead to injuries. Pain is a personal experience influenced by social, psychological, and physical elements (Raja et al., 2020). Numerous factors, such as trauma, illness, inflammation, and nerve damage, can cause it (Pinho-Ribeiro et al., 2017). Pain significantly affects a person's overall well-being, making it challenging to perform daily tasks, meet work responsibilities, and engage in social interactions (Katz, 2002). Pain perception involves sensory neuron firing, chemical and electrical impulses passing through neural pathways, and the interpretation of these signals by the higher brain centers (Yam et al., 2018). Pain perception is influenced by various systems, including the activation of nociceptors, and specialized sensory neurons that react to noxious stimuli (Dubin & Patapoutian, 2010). Nociceptors express ion channels triggered by heat, acid, and unpleasant stimuli, such as acid-sensing ion channels (ASICs) and transient receptor potential vanilloid 1 (TRPV1) (Ohashi & Kohno, 2020).

*Corresponding Author: **Ashvini Mansing Deshmukh**

Pain is an unpleasant sensory and emotional experience related to real or potential tissue harm. The numerical rating scale (NRS) is the most widely used anguish scale, assessing pain levels from 0 to 10. The pain threshold is a subjective phenomenon. Analgesics, such as NSAIDs, paracetamol, and opioids, are used to relieve pain, but they can have adverse effects and lead to dependence if not taken responsibly. Natural/herbal analgesics and anti-inflammatory medicines like capsaicin, camphor oil, curcumin, cod liver oil, and green tea are also used. Physical techniques for treating low backache include therapeutic heat, cryotherapy, ultrasonic therapy, and transcutaneous electrical nerve stimulation. Pain is often caused by strong or harmful stimuli, such as burning fingers or causing injury. Congenital insensitivity to pain (CIP) is a rare condition where a person cannot feel physical pain. Xenon Pharmaceutical developed XEN402 to cure pain by blocking voltage-dependent Na+ voltage gated channels. Pain is known as the "passion of the soul" and serves as a self-preservation mechanism, alerting the body to potential damage.

Pain is a personal experience influenced by social, psychological, and physical elements. (Raja et al., 2020). Numerous factors, such as trauma, illness, inflammation, and nerve damage, can cause it.(Pinho-Ribeiro et al., 2017) Pain can have a significant impact on a person's general well-being by making it more difficult for them to carry out everyday tasks, meet their duties at work, and engage in social contacts (Katz, 2002). The intricate process of pain perception includes the firing of sensory neurons, the passage of chemical and electrical impulses along neural pathways, and the higher brain centres' interpretation of these signals. (Yam et al., 2018). Numerous systems are involved in the creation and modification of pain perception.6 The activation of nociceptors, specialised sensory neurons that react to noxious stimuli, is one way.(Dubin & Patapoutian, 2010). Ion channels that are triggered by heat, acid, and other unpleasant stimuli are expressed by nociceptors. Examples of these channels are acid-sensing ion channels (ASICs) and transient receptor potential vanilloid 1 (TRPV1). (Ohashi & Kohno, 2020) When a neuron is depolarized by these ion channels, excitatory neurotransmitters like glutamate and substance P are released. These neurotransmitters excite nearby neurons and set off a chain reaction that sends messages up to the spinal cord. (Zieglgänsberger, 2019) The transmission of these signals via brain pathways, such as the spinothalamic tract, is another route. (Steeds, 2009). These impulses go through the spinal cord to secondary neurons, which then send the data to higher brain regions. (Alorfi, 2023) Numerous elements, including the stimulus's duration and severity, the person's mental state, and the environment in which the pain happens, might affect how someone perceives pain. (Ma et al., 2019). Several other mechanisms are also involved in the modulation of pain perception, one of which is the activation of descending pathways from higher brain centres to the spinal cord. (Yam et al., 2018) These pathways release neurotransmitters that lessen the experience of pain, such as enkephalins and endorphins, by inhibiting the release of other neurotransmitters implicated in pain transmission. (Park & Luo, 2010) Furthermore, tissue injury and inflammation can cause nociceptors to become sensitised, which can cause hyperalgesia or allodynia.(Schaible & Richter, 2004) All things considered, the processes underlying pain perception are intricate and entail the stimulation and regulation of numerous brain pathways and signalling molecules. Comprehending these mechanisms is imperative for the advancement of efficacious pain mitigation. One cannot undervalue the ubiquity and importance of pain as a medical condition. It impacts a sizable segment of the populace and has broad ramifications for people, the healthcare industry, and society at large. In the medical field, attempts to better control pain and enhance patient outcomes continue to be of utmost importance. Pharmacological and non-pharmacological techniques are used in a multidisciplinary approach to effectively manage pain, which is a crucial component of healthcare. (Andronis et al., 2017)

TYPES OF PAINKILLERS

NSAIDs, or non-steroidal anti-inflammatory drugs, are commonly used over-the-counter pain relievers for various conditions like headaches, dysmenorrhea, backaches, and toothaches, reducing temperature and pain (Figure 1).

NSAIDs, or non-steroidal anti-inflammatory drugs: NSAIDs, which do not include steroids and are the most common type of over-the-counter pain relievers, are used to treat a wide range of pain conditions, such as headaches, dysmenorrhea, backaches, and toothaches. NSAIDs reduce temperature as well as pain and inflammation. Acetyl salicylic acid (ASA), also known as aspirin, ibuprofen, diclofenac, and naproxen, are the NSAIDs that are widely accessible.



Figure 1: List of types of painkillers

PAINKILLERS

1. **Opioids:**

Opioids are popular and effective medications for treating severe pain, used for postsurgical, cancer, trauma, and final care. They are classified as strong or weak on the World Health Organisation pain ladder (Walsh et al., 2008). Opioids are a class of pharmaceuticals that includes compounds like heroin and legitimate prescription painkillers like oxycodone, hydrocodone, and morphine. They function by attaching to opioid receptors in the brain and body, thereby lowering the experience of pain and inducing feelings of euphoria. Opioids have the potential to be useful in the treatment of pain, but there is a risk of addiction, abuse, and overdose. The opioid crisis, which has resulted in a sharp rise in the number of prescriptions for opioids and deaths associated with them, has

*Corresponding Author: **Ashvini Mansing Deshmukh**

raised awareness of and regulations surrounding their use. In addition to counselling and support, medicines such as buprenorphine or methadone are frequently used in the treatment of opioid use disorder.

2. Paracetamol

Paracetamol, a popular analgesic, reduces pain and temperature but lacks anti-inflammatory properties. Combining with NSAIDs can be potent, but excessive use can cause liver damage. Although its precise mode of action is unknown, paracetamol acts by blocking specific brain enzymes that cause pain and heat. When taken as prescribed, it's generally regarded as safe, but consuming too much of it can harm your liver. To prevent unintentional overdosing, it's critical to adhere to dosage guidelines and use caution while taking it with other drugs that also include paracetamol.

3. Naproxen

NSAIDs like Ibuprofen, Naproxen, and Diclofenac are commonly used in dentistry for pain relief and analgesia, with Diclofenac sodium and potassium being the most commonly used (Velásquez et al., 2014). A nonsteroidal anti-inflammatory medicine (NSAID) called naproxen is used to treat fever, lessen inflammation, and relieve discomfort. It's frequently given for ailments like headaches, menstrual cramps, arthritis, and muscle soreness. Naproxen acts by preventing the body from producing prostaglandins, which are chemicals that cause pain and inflammation. It’s available over-the-counter at smaller doses and by prescription in bigger doses.

4. Aspirine

Acetylsalicylic acid, also known as aspirin, is a popular nonsteroidal anti-inflammatory medication (NSAID) that has anti-inflammatory, pain-relieving, and antipyretic (fever-reducing) qualities. It is frequently used to treat mild to severe pain, including headaches, aches in muscles, and arthritis. Aspirin acts by blocking the cyclooxygenase (COX) enzyme, which is essential for the synthesis of prostaglandins, which are substances that increase heat, discomfort, and inflammation.

Additional painkillers (Include all)

5. Camphor

Camphor, due to its counter-irritant and modest local anesthetic properties, is effective in treating dental caries pain and sensitivity, with higher concentrations showing notable antibacterial action against pathogenic Gram-positive bacteria. Camphor, a white, crystalline substance, is derived from the camphor tree's wood and has medicinal and therapeutic uses. Its analgesic, anti-inflammatory, and antiseptic properties are used in ointments and creams to relieve pain and reduce inflammation. However, it should be used cautiously, not on broken skin, and kept away from children.

6. Methanol

Melastatin 8, a non-selective cation receptor, is activated by menthol, providing a cooling sensation, according to a study by Alvarado et al (Alvarado et al., 2007). Methanol is highly hazardous to humans and can have major health consequences if consumed, breathed, or absorbed through the skin. Methanol poisoning symptoms include headache, dizziness, and nausea; in extreme situations, it can cause metabolic acidosis, blindness, or death. Because of its toxicity, methanol should be handled with attention, and safety precautions should always be taken when utilising items containing it.

USE OF PAINKILLERS

Dysmenorrhoea

Dysmenorrhea, a common gynecologic condition in young girls, can cause back, leg, nausea, vomiting, headache, dizziness, and diarrhea, often accompanied by lower abdominal pain or squeezing feelings (Agarwal & Agarwal, 2010). Dysmenorrhea is the pain associated with menstruation, which is often felt as cramps in the lower abdomen. There are two types: primary dysmenorrhea, which is associated with the menstrual cycle without underlying disorders, and secondary dysmenorrhea, which is caused by medical conditions such as endometriosis or fibroids.

Low backache

As we age, lumbar spine degeneration leads to back pain, often resulting in sciatica. Tramadol, a mild serotonin reuptake inhibitor, can be an effective pain reliever (Aronson, 1997). Low backache, often known as lower back pain, is a common condition that affects many people at least once in their lives. It can be caused by a variety of circumstances and can range from a minor discomfort to a severe, incapacitating agony.

Tricyclic Antidepressant

Gabapentin: This medication is being used more frequently to cure neuropathic pain (Braverman et al., 2001). Research suggests physical activity and comfort are effective in managing persistent low back pain, but insufficient evidence supports bed rest for chronic back pain treatment (Hong et al., 2022). Tricyclic antidepressants (TCAs) are a type of drug used largely to treat depression. They can help treat mental disorders, chronic pain, and certain forms of migraines. TCAs function by influencing neurotransmitters in the brain, specifically norepinephrine and serotonin, to improve mood and relieve symptoms.

Physical Modalities

The application of therapeutic heat involves applying superficial heat (Nadler et al., 2003) (hot packs) for 20–30 minutes or deep heat using ultrasonic therapy for 5–10 minutes. Short-wave therapy, cryotherapy, and electrotherapy are effective physical methods for pain reduction, reducing nerve transmission, and treating chronic low back pain (Gary, 1990). Physical modalities are therapeutic approaches and treatments meant to enhance function, encourage healing, and reduce discomfort. They are frequently used in areas related to physical therapy and rehabilitation.

Natural anti-inflammatory agents

Nutraceuticals from plants and animals are increasingly popular for pain relief due to their minimal adverse effects, often used for local application of traumatic injuries and muscular soreness (Roshal, 1987). According to Curtis et al.

*Corresponding Author: **Ashvini Mansing Deshmukh**

(Curtis et al., 2000), the application of omega-3 EFA fish oil (in the form of cod liver oil) to treat skeletal, muscular, and discogenic illnesses in the late 18th century. Curcumin, a naturally occurring yellow pigment, has been used in Chinese and Ayurvedic medicine for digestive issues, wound healing, and cystic fibrosis, while green tea is also effective in arthritis treatment (Sarla, 2020).

Appropriate pain treatment

Pain treatment involves neuropathic, nociceptive, or a mix of both drugs, with opioids and NSAIDs being essential, but both must be available, follow clinical guidelines, and integrate into complex therapeutic approaches (Noble et al., 2010). It is also evident that not every patient responds to opioids in the same way or at the same dose. (Smith, 2008) Some of the variances look like genetic, however, the exact nature of the differences is yet unknown. Variations in opioid receptors may result in varying degrees of analgesia. (Bayerer et al., 2007) Genetics also influence how opioids are metabolized, which may result in either high or low blood levels in a patient depending on how quickly or slowly they metabolize the drug (Samer et al., 2010). Any attempt to increase pain relief efforts must include the funding of training programs because understanding the proper application of pain medications (Trescot, Helm, et al., 2008), their metabolism (Trescot, Datta, et al., 2008), and the management of their side effects, which include addiction, are all essential to the safe and potential use of these medications. Opioid dependency and its relationship to pain management remain contentious. Medical professionals and the general population discourage opioid analgesics due to dependence risks. However, more research is needed to understand pain-affected individuals' reliance. Dependency is a bio-psycho-social phenomenon, combining susceptibility characteristics and physiological, behavioral, and cognitive phenomena (Webster & Webster, 2005).

Pain is described as a "unpleasant sensory or emotional experience associated with actual or potential tissue damage, or described in terms of such damage" by the International Association for the Study of Pain (IASP) in 1979.26 About 22% of primary care patients globally report having considerable, persistent pain, according to WHO data.(Gureje et al., 1998)

The appropriate usage of drugs for the treatment of pain is determined by the source of the pain signal. It is possible to classify pain as nociceptive, neuropathic, or a mix of the two. Clinicians are most familiar with nociceptive pain, which results from injuries to the body (skin, bones, muscles, and viscera) as opposed to the central or peripheral neural systems.

Opioids and nonsteroidal anti-inflammatory medications (NSAIDs) are typically effective in treating this type of pain. "Any pain initiated or caused by a primary lesion or dysfunction of the nervous system" is referred to as neuropathic pain. Opioid medications work for a subset of neuropathic pain sufferers.

Therefore, recognising the type of pain and matching it to the best treatment is necessary for the rational use of drugs. When a patient is first experiencing pain, physical modalities like ice and heat are used in addition to moderate analgesics like acetaminophen/paracetamol. It makes sense to use anti-inflammatory medications, including nonsteroidal (NSAIDs) and steroids, to relieve pain brought on by inflammation. When treating moderate to severe pain, opioid analgesics are crucial, especially for those who are not responding to other forms of analgesic therapy. When used logically as analgesics, opioids would be incorporated into a multifaceted therapeutic plan.

While opioid analgesics are necessary for adequate pain management, they shouldn't be the only class of drugs used to treat pain, especially mild to moderate pain. For proper pain treatment, both opioid and non-opioid analgesics should be made available. Their reasonable usage should also adhere to clinical assessment guidelines, proportionality intervention requirements, and pharmacological principles for integration into complicated therapeutic approaches. Opioid medications are safe when used as prescribed, and individuals hardly ever develop an opioid analgesic dependence. (Noble et al., 2010)

It is also evident that not every patient responds to opioids in the same way or at the same dose. (Smith, 2008) Some of the variances seem to be genetic, however the exact nature of the differences is yet unknown. Variations in opioid receptors can result in varying degrees of analgesia.(Bayerer et al., 2007) Genetics also influence how opioids are metabolised, which can result in either high or low blood levels in a patient depending on how quickly or slowly they metabolise the drug. (Samer et al., 2010) Concomitant drugs that affect how opioids are metabolised could be the cause of additional variations in how people react to opioids. For instance, taking numerous drugs together, particularly antidepressants, will prevent some opioids from being metabolised. The aforementioned research highlights the significance of managing pain through individualised treatment plans that include customised dosage and administration schedules.

Any attempt to increase pain relief efforts must include the funding of training programmes because understanding the proper use of pain medications(Trescot, Helm, et al., 2008), their metabolism (Trescot, Datta, et al., 2008), and the management of their side effects, including addiction, are all essential to the safe and effective use of these medications.

Opioid dependency and its relationship to pain management are still contentious issues. On the one hand, medical professionals and the general population are discouraged from using opioid analgesics due to the risk of opioid dependence. However, further research is needed to fully understand the data around reliance in pain-affected people. All people who are regularly exposed to opioids experience tolerance and withdrawal, which are significant but insufficient symptoms on their own to establish dependency. According to current understanding, dependence is a bio-psycho-social phenomenon that combines susceptibility characteristics and physiological, behavioural, and cognitive phenomena. While

*Corresponding Author: **Ashvini Mansing Deshmukh**

tolerance and withdrawal symptoms are developed, most people receiving opioid analgesics for pain do not exhibit the susceptibility traits that lead to the development of dependence (Webster & Webster, 2005).

While the likelihood of developing an opioid addiction is extremely low among patients receiving pain management, it may be more substantial in certain individuals with a particular history of sensitivity. Therefore, to provide effective pain management while avoiding unintended outcomes like dependency or diversion, intensive clinical monitoring and a customised approach for each patient are required.(Ballantyne & Shin, 2008), (Passik, 2009), (Chou et al., 2009) Nevertheless, using opiates to manage pain is not prohibited by dependence alone.

DEVELOPMENTAL ASPECTS OF ACCESS TO CONTROLLED MEDICINES

The General Assembly Resolution emphasized the need for coordinated action at national, regional, and global levels to address developmental and other problems caused by noncommunicable illnesses (Stylianou et al., 2015). This should be understood to apply to both preventive and curative medications and the availability of opioid analgesics to treat the pain (Figure 2).

The international development agenda, which acknowledges the critical role that health plays in social and economic development as well as the necessity of medicines for good health, places a strong emphasis on access to medications. The MDGs' Target 8.E, "In cooperation with pharmaceutical companies, provide access to affordable essential drugs in developing countries," particularly addresses it. The United Nations General Assembly pledged to "accelerating progress in promoting global public health for all" at the September 2010 UN Millennium Development Goals Review by bolstering global collaboration to improve medication access.

A high-level meeting on the prevention and control of non-communicable diseases is scheduled for September 2011 by the United Nations General Assembly. The meeting will centre on the four most common non-communicable diseases, which are diabetes, cancer, chronic respiratory diseases, and cardiovascular disorders. "Underscored the need for concerted action and a coordinated response at the national, regional, and global levels in order to adequately address the developmental and other challenges posed by non-communicable diseases," read the General Assembly Resolution that decided to organise this high-level meeting. (Stylianou et al., 2015) The General Assembly expressed concern about the fact that millions of people worldwide still lack access to affordable, safe, and high-quality medications and reiterated the need to expand global collaboration in the creation of these drugs. This should be understood to apply to both preventive and curative medications as well as the availability of opioid analgesics for the treatment of pain.

In Resolution 53/4, the Commission asked Member States to think about how to use current health and development initiatives in nations lacking sufficient access to psychotropic and narcotic drugs for scientific and medical purposes, including enhancing those nations' capabilities through training.



Figure 2 : Drug Delivery Systems for Pain Management

A GUIDE TO SAFE USE OF PAIN MEDICINE

FDA-regulated pain relief medications, prescribed by medical professionals, work on nerve systems to alleviate physical pains and prevent specific molecules from forming, based on source and severity.

Pain relief medications exist in a variety of forms and strengths, can be purchased over-the-counter (OTC) or with a prescription, and they can be used to treat any kind of physical pain, including pain from cancer, acute trauma, and chronic illnesses. The Food and Drug Administration (FDA) is in charge of regulating painkillers and analgesics, other names for pain management medications. Certain analgesics, such as opioid analgesics, block or lessen sensitivity to pain by acting on the body's peripheral and central nerve systems. Others work by preventing specific molecules from being formed within the body.

When advising or prescribing them, medical professionals take into account many criteria, including the source and severity of the pain.

Use as directed

Misuse of painkillers can lead to severe harm, so patients should follow healthcare advice, use measuring tools, consult a physician, and avoid sharing.

With NSAIDs

Reflux can cause stomach bleeding, kidney damage, and sleepiness in older individuals, especially those with a history of bleeding, high blood pressure, heart disease, or kidney illness.

*Corresponding Author: **Ashvini Mansing Deshmukh**

MISUSE AND ABUSE

Misuse of opioids, particularly codeine, Oxycontin, Vicodin, and Demerol, poses serious public safety risks, leading to addiction and overdose deaths when taken incorrectly. The misuse and abuse of painkillers can be quite harmful. This is particularly true with reference to opioids. It is important to keep these prescription drugs in a location that is secure against theft. The National Institutes of Health reports that research has demonstrated the safe, efficient management of pain, and low risk of addiction associated with the medicinal use of opioid analgesic chemicals when taken exactly as recommended. However, the misuse of opioids poses a serious risk to public safety. Abusers swallow these substances orally, crushing the pills before injecting or snorting them. Prescription medications like codeine and name-brand goods Oxycontin (oxycodone), Vicodin (hydrocodone with acetaminophen) and Demerol (mepheridine) are among the often abused opioid painkillers. Addiction is among the worst risks associated with opioid misuse. Snorting and injecting opioids—especially OxyContin, which was intended to be a slow-release formulation—has led to a number of overdose deaths.

1. Side effects of pain killer medicines:

Proton pump inhibitors like omeprazole and pantoprazole reduce NSAID side effects, while long-term diclofenac use increases cardiovascular risks. Alternatives include ibuprofen, naproxen, and acetaminophen. By utilising proton pump inhibitors like omeprazole or pantoprazole, the most common side effects of NSAIDs, such as indigestion, gastritis, ulcers, and gastrointestinal bleeding, can be greatly minimised. Additionally, a few studies have demonstrated that using diclofenac for longer than two to four weeks raises the risk of cardiovascular illnesses. Low doses of ibuprofen, naproxen, or acetaminophen (paracetamol) are safer options for people with cardiovascular disease. Acetaminophen (paracetamol) is an alternative because taking NSAIDs can raise the risk of acute renal failure in persons with impaired kidney function. It is not advised for patients with stomach erosions and ulcers, nor for those who are pregnant in the first few weeks, to take NSAIDs. Acetaminophen is not recommended for liver disease sufferers.

PAIN MANAGEMENT

Pharmacological pain management techniques include adjuvant analgesics, corticosteroids, and non-opioid and opioid analgesics. Non-opioid analgesics treat mild to moderate pain, while opioids treat moderate to severe pain, but have side effects (Dharmshaktu et al., 2012). Corticosteroids are potent anti-inflammatory drugs commonly used to manage inflammation-related pain, particularly in treating back and rheumatoid arthritis-related issues (Vyvey, 2010). By adjusting the nervous system's activity using methods like transcutaneous electrical nerve stimulation, spinal cord stimulation, and deep brain stimulation, emerging pain therapies like neuromodulation for pain provide novel ways to relieve chronic pain (Yu et al., 2020). The optimal drug and dosage schedule for pain management depends on the specific patient's circumstances, including the type and extent of their discomfort (Fink, 2000).

Adjuvant analgesics, corticosteroids, and non-opioid and opioid analgesics are examples of pharmacological pain management techniques. It's usual practice to address mild to moderate pain with non-opioid analgesics. Strong painkillers called opioid analgesics are used to treat moderate to severe pain. They do, however, come with several side effects, such as constipation, respiratory depression, and sedation. Addiction and dependency are major risks associated with opioid medications. Adjuvant analgesics can also improve pain relief; examples of these are antidepressants and anticonvulsants.(Dharmshaktu et al., 2012) Strong anti-inflammatory drugs called corticosteroids are used to treat inflammation-related pain. They are frequently used to treat back pain and pain brought on by illnesses like rheumatoid arthritis. (Vyvey, 2010) By adjusting the nervous system's activity using methods like transcutaneous electrical nerve stimulation, deep brain stimulation, and spinal cord stimulation, emerging pain therapies like neuromodulation for pain provide novel ways to relieve chronic pain.(Yu et al., 2020)

The best drug and dosage schedule for managing pain depend greatly on the circumstances unique to each patient. The kind and degree of the patient's discomfort is one crucial set of variables to take into account. (Fink, 2000) The type and degree of pain the patient is experiencing affects the prescription that is selected. The existence of underlying medical issues is another important consideration. To reduce the risk of side effects or drug interactions, patients with comorbidities such as liver or renal illness, cardiovascular disorders, or gastrointestinal problems, may need to have their prescription selection or dosage modified. Physiological changes associated with ageing may also influence drug choice. Patients who are elderly may have changed pharmacokinetics and pharmacodynamics, which increases their vulnerability to side effects. They might therefore need other, better-tolerated drugs or smaller dosages. To find any drug interactions, the patient's medication profile must be evaluated. Analgesics and some drugs may interact, changing their effectiveness or raising the possibility of negative side effects. It is essential to take concurrent medicine into account to prevent undesired reactions. Ensuring efficient pain management is crucial for improving the quality of life for those who experience pain. Pharmacological techniques for pain reduction are a crucial part of pain management plans and ought to be applied carefully to maximise benefits and reduce side effects

Non-Opioid Analgesics

Medications known as non-opioid analgesics are frequently used to treat mild to severe pain (Schug et al., 2003). Aspirin, acetaminophen, and nonsteroidal anti-inflammatory medications (NSAIDs) like naproxen and ibuprofen are a few examples. These medications have a minimal risk of addiction and dependence and are generally accessible over the counter.

*Corresponding Author: **Ashvini Mansing Deshmukh**

Types of Non-Opioid Analgesics

Paracetamol, NSAIDs, and topical treatments are the three main categories of non-opioid analgesics. The most widely utilized class of non-opioid analgesics is NSAIDs (Pope & Deer, 2017). They function by preventing prostaglandins, which cause pain and inflammation, from being produced (Pountos et al., 2011). Two further classifications for NSAIDs are selective and non-selective. Nonselective NSAIDs target COX-1 and COX-2 enzymes, whereas selective NSAIDs mainly target COX-2 (cyclooxygenase-2) enzymes (Bens et al., 2019). Ibuprofen, naproxen, and aspirin are examples of non-selective NSAIDs, whereas celecoxib is an example of a selective NSAID (Schug et al., 2003). Paracetamol helps to treat mild to moderate pain, but it is ineffective in lowering inflammation (Botting, 2000). Topical agents include items like capsaicin cream and diclofenac gel (Sawynok, 2005).

Pharmacological Effects and Mechanism of Action

NSAIDs function by preventing the production of prostaglandins by the COX enzymes (Langford, 2006). The mechanism of action of paracetamol is to prevent the central nervous system from producing prostaglandins. Topical medications function by obstructing pain signals where they are applied (Argoff, 2013). NSAIDs also possess antipyretic, anti-inflammatory, and antiplatelet properties in their pharmacological actions. (Margareth, 2017) They achieve this by blocking the production of inflammatory mediators such cytokines and chemokines (Ziccardi et al., 2002).

The mechanism of action of non-opioid analgesics is to prevent the synthesis of prostaglandins, which cause inflammation and pain. NSAIDs function by preventing the production of prostaglandins by the COX enzymes. (Langford, 2006) The mechanism of action of paracetamol is to prevent the central nervous system from producing prostaglandins. Topical medications function by obstructing pain signals where they are applied. (Argoff, 2013) NSAIDs also possess anti-inflammatory, antipyretic, and antiplatelet properties in their pharmacological actions. (Margareth, 2017) They do this by preventing the synthesis of inflammatory mediators such as chemokines and cytokines. (Ziccardi et al., 2002) By preventing the synthesis of prostaglandins, which control body temperature, they also lower fever. (Mattam et al., 2021) Finally, there is antiplatelet action in NSAIDs.(Marsico et al., 2017)

ADVERSE EFFECTS

Because non-opioid analgesics can have negative side effects, they might not be able to be taken (Labianca et al., 2012). Although paracetamol is usually easily tolerated, an excess can be harmful to the liver (Ramachandran & Jaeschke, 2019). Topical medications can cause local and systemic side effects, such as burning, itching, and skin irritation if absorbed through the skin (Hengge et al., 2006).

Opioid Analgesics

When it comes to treating pain, opioid analgesics are the most effective drugs (Schug et al., 2003). But they possess a variety of pharmacological effects, such as analgesia, euphoria, respiratory depression, and sedation (Kotlińska-Lemieszek & Żylicz, 2022). Long-term usage of opioid analgesics can result in gastrointestinal adverse effects, respiratory depression, addiction, tolerance, dependence, and hormonal imbalances and abnormalities (Kotlińska-Lemieszek & Żylicz, 2022).

Types of Opioid Analgesics

Opioid analgesics are categorized into natural, synthetic, and semi-synthetic types, derived from opium poppy, and produced in labs.

Pharmacological Effects and Mechanism of Action

The complex and multi-step mechanism of action of opioid analgesics consists of neurotransmitter inhibition, G protein activation, and receptor binding (Valentino & Volkow, 2018). Through the targeting of opioid receptors in various body areas, these drugs effectively reduce the perception of pain and provide patients with mild to severe pain relief (Parsells Kelly et al., 2008).

Adverse Effects

The most common side effects include vertigo, drowsiness, addiction, disorientation, and respiratory depression; they are all associated with the central nervous system (H. & P., 2010). Since respiratory depression from opioid analgesics can be lethal, patients on these medications need to be closely watched (Pattinson, 2008). Hormonal abnormalities, such as elevated prolactin and low testosterone, can also be brought on by opioid analgesics (Seyfried & Hester, 2012). Opioid analgesic dependence, tolerance, and addiction are possible outcomes of long-term use (Morgan & Christie, 2011). Long-term users of opioid analgesics could need bigger dosages to get the same amount of pain relief (Alford et al., 2006). Agitation, anxiety, and flu-like symptoms are among the withdrawal symptoms that can occur after abruptly stopping opioid medications (Wallace & Papp, 2017).

Adjuvant Analgesics

Adjuvant analgesics are a broad family of medications that are used in conjunction with other painkillers to enhance their analgesic effects or to treat specific types of pain (Khan et al., 2011). These medications work by modulating the ion channels and neurotransmitter activity of the central and peripheral nervous systems. Benzodiazepines, corticosteroids, anticonvulsants, and antidepressants are examples of adjuvant analgesics (Knotkova & Pappagallo, 2007).

Categories of Adjuvant Analgesics

Adjuvant analgesics fall into several groups according to their therapeutic indications and mode of action. Among these categories are:

Antidepressants

Pain management has made use of antidepressants, especially those that interfere with serotonin and noradrenaline signaling (Anastasiou et al., 2014). These drugs work by changing the descending pain pathways that travel from the brainstem to the spinal cord, thereby reducing pain perception (Dharmshaktu et al., 2012).

Anticonvulsants

Anticonvulsants, like pregabalin and gabapentin, have shown promise as treatments for neuropathic pain (Durkin et al., 2010). Anticonvulsants have also been demonstrated to alleviate depression, anxiety, and poor sleep, all of which are frequent comorbidities in individuals with chronic pain (Argoff, 2007). Anticonvulsants are useful in the treatment of several neuropathic pain syndromes, such as diabetic neuropathy, postherpetic neuralgia, and spinal cord injury, according to clinical studies (Jensen, 2002).

Local Anesthetics

To treat chronic pain, local anesthetics such as bupivacaine and lidocaine can be utilized (Deer et al., 2002). They relieve pain and cause a temporary lack of feeling by obstructing the nerve impulses in a particular body location. (Yanagidate & Strichartz, 2007) the blockage of voltage-gated sodium channels in nerve fibers is the main mode of action of local anesthetics (Scholz, 2002). The anesthetic is injected into the cerebrospinal fluid or the epidural space via an intrathecal injection, respectively (Bucklin et al., 2002).

Corticosteroids

Due to their strong analgesic and anti-inflammatory properties, corticosteroids are helpful in the treatment of a range of pain conditions. They lessen the synthesis of chemicals that lead to pain and mediators of inflammation, like prostaglandins, leukotrienes, and cytokines (Vyvey, 2010). Corticosteroids, which include dexamethasone and prednisone, can be used in the treatment of inflammatory discomfort. Additionally, corticosteroids decrease the immune system, which is advantageous when treating autoimmune disease-related pain, which includes rheumatoid arthritis (Coutinho & Chapman, 2011). However, prolonged usage of corticosteroids can also result in infections, osteoporosis, and muscle weakness (Oray et al., 2016). Table 1 provides a tabular summary of the available pharmaceutical choices for pain management.

Table 1: Pharmacological options for pain management

Class	Examples	Role in Pain
Non-opioid analgesics	Aspirin, acetaminophen, (NSAIDs) such as ibuprofen and naproxen	They function by preventing the synthesis of prostaglandins, which cause inflammation and pain.
Opioid analgesics	Morphine, oxycodone, hydrocodone, fentanyl, and codeine	Inhibition of opioid receptor
Anti-depressants	SSRIs such as paroxetine and fluoxetine TCAs such as amitriptyline and nortriptyline	blocking the transporters of serotonin or norepinephrine
Benzo-diazepines	Diazepam	inhibit the brain's GABA neurotransmitter
Anticonvulsants	Gabapentin and pregabalin	reduction in the influx of calcium ions, which results in the release of less glutamate and sensory neuropeptides (Substance P and CGRP) at the synapses.
Local Anesthetics	Lidocaine and bupivacaine	blocking of the Na+ and K+ ion channels, which control the amounts of calcium both inside and outside of cells
Cortico-steroids	Prednisone and dexamethasone	An anti-inflammatory action

Emerging Therapies

Using chemical or electrical stimulation to alter the nervous system's function and reduce pain is a treatment approach known as neuromodulation (Yu et al., 2020). It is intended for persistent pain disorders that have not improved with conventional therapy. Spinal cord stimulation (SCS) is a popular technique in which a tiny gadget is implanted close to the spinal cord to provide electrical impulses that block pain signals (Anastasiou et al., 2014). In general, neuromodulation for pain offers an alternate strategy that directly affects the neurological circuits involved in pain perception, providing relief and enhanced functionality for people with chronic pain.

Non-Pharmacological Interventions

Non-pharmacological approaches for pain treatment, which do not involve pharmaceuticals, involve supplementary, physical, or psychological therapies, as listed in Table 2.

Table 2: Non-Pharmacological Options for Pain Management

Approach	Description
Physical Therapy	This method involves manual techniques, athletic movements, and muscle stretches to enhance body flexibility, strength, and mobility, often used to treat injuries, musculoskeletal disorders, or post-surgery healing (George & Goode, 2020) includes methods such as transcutaneous electrical nerve stimulation (TENS), ultrasound, heat or cold therapy, and massage (Rakel & Barr, 2003).

*Corresponding Author: **Ashvini Mansing Deshmukh**

Psychological Interventions	uses cognitive-behavioral therapy (CBT) to change pain-related emotions, beliefs, and behaviors. This program provides individuals with coping mechanisms, stress-reduction techniques, and relaxation techniques to improve functional results and pain perception, particularly beneficial for long-term pain syndromes like fibromyalgia and persistent low back pain
Complementary and Alternative Medicine (CAM)	CAM therapies, including yoga, acupuncture, mindfulness meditation, and herbal medicines, aim to alleviate pain, promote stress relief, and enhance bodily awareness, with varying effectiveness (Tournaire & Theau-Yonneau, 2007).
Combination Approach	Healthcare practitioners can enhance pain management by combining non-pharmacological methods with pharmaceutical methods and providing personalized interventions to meet individual patient needs and preferences.

CONCLUSION

Common pain medications include opioids, NSAIDs, anticonvulsants, and antidepressants. Opioids are used for acute pain but can lead to addiction. NSAIDs are useful for inflammatory pain but have side effects. Anticonvulsants and antidepressants are used for neuropathic pain. Careful patient selection and dosage are necessary. In general, to provide the best pain relief and enhance the quality of life, pharmacological pain management techniques should be utilized carefully and customized to each patient's needs. NSAIDs are used as analgesics for various pain conditions like headaches, dysmenorrhoea, backache, and toothache. They reduce inflammation, lower fever, and have antipyretic properties. Home remedies like cinnamon and anise tea manage dysmenorrhoea. Opioids are used for severe pain (Devi et al., 2020). Emerging trends in pharmacological pain management focus on novel therapeutic targets and creative drug delivery strategies, utilizing advanced technologies and understanding pain causes (Alorfi, 2023).

FUTURE RESEARCH AND UPCOMING CONSIDERATIONS

Novel therapeutic targets and creative drug delivery strategies are the main topics of emerging trends in pharmacological pain management. Researchers and pharmaceutical companies aim to create more effective, customised and targeted pain relief drugs by leveraging cutting-edge technologies and deepening their understanding of pain causes. (Alorfi, 2023)

ACKNOWLEDGMENT:

The authors are thankful to S.B.B. Alias Appasaheb Jedhe College Pune for providing their support.

REFERENCES:

1. Agarwal, A., & Agarwal, A. (2010). A study of dysmenorrhea during menstruation in adolescent girls. *Indian Journal of Community Medicine*, *35*(1), 159–164. https://doi.org/10.4103/0970-0218.62586
2. Alford, D. P., Compton, P., & Samet, J. H. (2006). Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy Annals of Internal Medicine Perspective Downloaded From: http://annals.org/ by a MIT Libraries User on 08/01/2013. *Annals of Internal Medicine*, *144*. www.annals.org
3. Alorfi, N. M. (2023). Pharmacological Methods of Pain Management: Narrative Review of Medication Used. *International Journal of General Medicine*, *Volume 16*(July), 3247–3256. https://doi.org/10.2147/ijgm.s419239
4. Alvarado, L. T., Perry, G. M., Hargreaves, K. M., & Henry, M. A. (2007). TRPM8 Axonal Expression is Decreased in Painful Human Teeth with Irreversible Pulpitis and Cold Hyperalgesia. *Journal of Endodontics*, *33*(10), 1167–1171. https://doi.org/10.1016/j.joen.2007.06.018
5. Anastasiou, E., Lorentz, K. O., Stein, G. J., & Mitchell, P. D. (2014). Prehistoric schistosomiasis parasite found in the Middle East. *The Lancet Infectious Diseases*, *14*(7), 553–554. https://doi.org/10.1016/S1473-3099(14)70794-7
6. Argoff, C. E. (2007). The coexistence of neuropathic pain, sleep, and psychiatric disorders : A novel treatment approach. *Clinical Journal of Pain*, *23*(1), 15–22. https://doi.org/10.1097/01.ajp.0000210945.27052.b3
7. Argoff, C. E. (2013). Topical analgesics in the management of acute and chronic pain. *Mayo Clinic Proceedings*, *88*(2), 195–205. https://doi.org/10.1016/j.mayocp.2012.11.015
8. Bayerer, B., Stamer, U., Hoeft, A., & Stüber, F. (2007). Genomic variations and transcriptional regulation of the human μ-opioid receptor gene. *European Journal of Pain*, *11*(4), 421–427. https://doi.org/10.1016/j.ejpain.2006.06.004
9. Bens, A., Cronin-Fenton, D., Dehlendorff, C., Jensen, M. B., Ejlertsen, B., Kroman, N., Friis, S., & Mellemkjær, L. (2019). Nonaspirin NSAIDs and contralateral breast cancer risk. *International Journal of Cancer*, *144*(6), 1243–1250. https://doi.org/10.1002/ijc.31949
10. Botting, R. M. (2000). Mechanism of action of acetaminophen: Is there a cyclooxygenase 3? *Clinical Infectious Diseases*, *31*(SUPPL. 5), 202–210. https://doi.org/10.1086/317520
11. Braverman, D. L., Slipman, C. W., & Lenrow, D. A. (2001). Using gabapentin to treat failed back surgery syndrome caused by epidural fibrosis: A report of 2 cases. *Archives of Physical Medicine and Rehabilitation*, *82*(5), 691–693. https://doi.org/10.1053/apmr.2001.21867
12. Bucklin, B. A., Chestnut, D. H., & Hawkins, J. L. (2002). Intrathecal opioids versus epidural local anesthetics for labor analgesia: A meta-analysis. *Regional Anesthesia and Pain Medicine*, *27*(1), 23–30. https://doi.org/10.1053/rapm.2002.29111

*Corresponding Author: **Ashvini Mansing Deshmukh**

13. Coutinho, A. E., & Chapman, K. E. (2011). The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. *Molecular and Cellular Endocrinology*, *335*(1), 2–13. https://doi.org/10.1016/j.mce.2010.04.005
14. Curtis, C. L., Hughes, C. E., Flannery, C. R., Little, C. B., Harwood, J. L., & Caterson, B. (2000). n-3 Fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. *Journal of Biological Chemistry*, *275*(2), 721–724. https://doi.org/10.1074/jbc.275.2.721
15. Deer, T. R., Serafini, M., Buchser, E., Ferrante, F. M., & Hassenbusch, S. J. (2002). Intrathecal bupivacaine for chronic pain: A review of current knowledge. *Neuromodulation*, *5*(4), 196–207. https://doi.org/10.1046/j.1525-1403.2002.02030.x
16. Devi, A. R., Baran, A., Bidhan, S., & Krishi Viswavidyalaya, C. (2020). Pain and Different Types of Pain Killers. *Researchgate.Net*, *June*, 31–46. https://www.researchgate.net/profile/Gurmeet-Sarla-2/publication/341941548_Pain_and_different_types_of_pain_killers/links/5eda6736299bf1c67d41d98c/Pain-and-different-types-of-pain-killers.pdf
17. Dharmshaktu, P., Tayal, V., & Kalra, B. S. (2012). Efficacy of antidepressants as analgesics: A review. *Journal of Clinical Pharmacology*, *52*(1), 6–17. https://doi.org/10.1177/0091270010394852
18. Dubin, A. E., & Patapoutian, A. (2010). Nociceptors: The sensors of the pain pathway. *Journal of Clinical Investigation*, *120*(11), 3760–3772. https://doi.org/10.1172/JCI42843
19. Durkin, B., Page, C., & Glass, P. (2010). Pregabalin for the treatment of postsurgical pain. *Expert Opinion on Pharmacotherapy*, *11*(16), 2751–2758. https://doi.org/10.1517/14656566.2010.526106
20. Fink, R. (2000). Pain Assessment: The Cornerstone to Optimal Pain Management. *Baylor University Medical Center Proceedings*, *13*(3), 236–239. https://doi.org/10.1080/08998280.2000.11927681
21. Gary, P. H. . J. B. M. . S. C. T. et al. (1990). The New England Journal of Medicine Downloaded from nejm.org on April 1, 2015. For personal use only. No other uses without permission. Copyright © 1990 Massachusetts Medical Society. All rights reserved. *The New English Journal of Medicine*, *323*(16), 1120–1123.
22. George, S. Z., & Goode, A. P. (2020). Physical therapy and opioid use for musculoskeletal pain management: Competitors or companions? *Pain Reports*, *5*(5), E827. https://doi.org/10.1097/PR9.0000000000000827
23. H., S., & P., B. (2010). Implications of opioid analgesia for medically complicated patients. *Drugs and Aging*, *27*(5), 417–433. https://rd.springer.com/openurl?genre=article&id=doi:10.2165/11536540-000000000-00000%0Ahttps://rd.springer.com/openurl?genre=article&genre=article&genre=article&issn=1170-229X&eissn=1179-1969&atitle=Implications+of+opioid+analgesia+for+medically+complica
24. Hengge, U. R., Ruzicka, T., Schwartz, R. A., & Cork, M. J. (2006). Adverse effects of topical glucocorticosteroids. *Journal of the American Academy of Dermatology*, *54*(1), 1–15. https://doi.org/10.1016/j.jaad.2005.01.010
25. Hong, J. Y., Song, K. S., Cho, J. H., Lee, J. H., & Kim, N. H. (2022). An Updated Overview of Low Back Pain Management. *Asian Spine Journal*, *16*(6), 968–982. https://doi.org/10.31616/asj.2021.0371
26. Jensen, T. S. (2002). Anticonvulsants in neuropathic pain: Rationale and clinical evidence. *European Journal of Pain*, *6*(SUPPL. 1), 61–68. https://doi.org/10.1053/eujp.2001.0324
27. Katz, N. (2002). The impact of pain management on quality of life. *Journal of Pain and Symptom Management*, *24*(1 SUPPL. 1), 38–47. https://doi.org/10.1016/S0885-3924(02)00411-6
28. Khan, M. I. A., Walsh, D., & Brito-Dellan, N. (2011). Opioid and adjuvant analgesics: Compared and contrasted. *American Journal of Hospice and Palliative Medicine*, *28*(5), 378–383. https://doi.org/10.1177/1049909111410298
29. Knotkova, H., & Pappagallo, M. (2007). Adjuvant Analgesics. *Anesthesiology Clinics*, *25*(4), 775–786. https://doi.org/10.1016/j.anclin.2007.07.006
30. Kotlińska-Lemieszek, A., & Żylicz, Z. (2022). Less Well-Known Consequences of the Long-Term Use of Opioid Analgesics: A Comprehensive Literature Review. *Drug Design, Development and Therapy*, *16*, 251–264. https://doi.org/10.2147/DDDT.S342409
31. Labianca, R., Sarzi-Puttini, P., Zuccaro, S. M., Cherubino, P., Vellucci, R., & Fornasari, D. (2012). Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. *Clinical Drug Investigation*, *32*(SUPPL. 1), 53–63. https://doi.org/10.2165/11630080-000000000-00000
32. Langford, R. M. (2006). Pain management today - What have we learned? *Clinical Rheumatology*, *25*(SUPPL. 7), 2–8. https://doi.org/10.1007/s10067-006-0311-5
33. Margareth, H. (2017). No Title العربية اللغة تدريس طرق. *Экономика Региона*, 32. https://doi.org/10.1002/eji.201445222.This
34. Morgan, M. M., & Christie, M. J. (2011). Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. *British Journal of Pharmacology*, *164*(4), 1322–1334. https://doi.org/10.1111/j.1476-5381.2011.01335.x
35. Nadler, S. F., Steiner, D. J., Erasala, G. N., Hengehold, D. A., Abeln, S. B., & Weingand, K. W.

(2003). Continuous low-level heatwrap therapy for treating acute nonspecific low back pain. *Archives of Physical Medicine and Rehabilitation*, *84*(3 SUPPL. 1), 329–334. https://doi.org/10.1053/apmr.2003.50102

36. Noble, M., Treadwell, J. R., Tregear, S. J., Coates, V. H., Wiffen, P. J., Akafomo, C., Schoelles, K. M., & Chou, R. (2010). Long-term opioid management for chronic noncancer pain. *Cochrane Database of Systematic Reviews*, *2018*(3). https://doi.org/10.1002/14651858.CD006605.pub2
37. Ohashi, N., & Kohno, T. (2020). Analgesic Effect of Acetaminophen: A Review of Known and Novel Mechanisms of Action. *Frontiers in Pharmacology*, *11*(November), 1–6. https://doi.org/10.3389/fphar.2020.580289
38. Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., & Foster, C. S. (2016). Long-term side effects of glucocorticoids. *Expert Opinion on Drug Safety*, *15*(4), 457–465. https://doi.org/10.1517/14740338.2016.1140743
39. Parsells Kelly, J., Cook, S. F., Kaufman, D. W., Anderson, T., Rosenberg, L., & Mitchell, A. A. (2008). Prevalence and characteristics of opioid use in the US adult population. *Pain*, *138*(3), 507–513. https://doi.org/10.1016/j.pain.2008.01.027
40. Pinho-Ribeiro, F. A., Verri, W. A., & Chiu, I. M. (2017). Nociceptor Sensory Neuron–Immune Interactions in Pain and Inflammation. *Trends in Immunology*, *38*(1), 5–19. https://doi.org/10.1016/j.it.2016.10.001
41. Pope, J. E., & Deer, T. R. (2017). Treatment of Chronic Pain Conditions: A Comprehensive Handbook. *Treatment of Chronic Pain Conditions: A Comprehensive Handbook*, 1–358. https://doi.org/10.1007/978-1-4939-6976-0
42. Pountos, I., Georgouli, T., Bird, H., & Giannoudis, P. V. (2011). Nonsteroidal anti-inflammatory drugs: Prostaglandins, indications, and side effects. *International Journal of Interferon, Cytokine and Mediator Research*, *3*(1), 19–27. https://doi.org/10.2147/IJICMR.S10200
43. Raja, S. N., Carr, D. B., Cohen, M., Finnerup, N. B., Flor, H., Gibson, S., Keefe, F. J., Mogil, J. S., Ringkamp, M., Sluka, K. A., Song, X. J., Stevens, B., Sullivan, M. D., Tutelman, P. R., Ushida, T., & Vader, K. (2020). The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain*, *161*(9), 1976–1982. https://doi.org/10.1097/j.pain.0000000000001939
44. Rakel, B., & Barr, J. O. (2003). Physical modalities in chronic pain management. *Nursing Clinics of North America*, *38*(3), 477–494. https://doi.org/10.1016/S0029-6465(02)00097-X
45. Ramachandran, A., & Jaeschke, H. (2019). Acetaminophen Hepatotoxicity. *Seminars in Liver Disease*, *39*(2), 221–234. https://doi.org/10.1055/s-0039-1679919
46. Roshal, J. Y. (1987). Treatment of chronic postherpetic neuralgia with topical capsaicin: A preliminary study. *Journal of the American Academy of Dermatology*, *17*(1), 93–96. https://doi.org/10.1016/S0190-9622(87)70178-9
47. Samer, C. F., Daali, Y., Wagner, M., Hopfgartner, G., Eap, C. B., Rebsamen, M. C., Rossier, M. F., Hochstrasser, D., Dayer, P., & Desmeules, J. A. (2010). Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. *British Journal of Pharmacology*, *160*(4), 919–930. https://doi.org/10.1111/j.1476-5381.2010.00709.x
48. Sarla, G. S. (2020). *Caffeine Containing Beverages : Health Effects Iatrology Archives Caffeine Containing Beverages : Health Effects Keywords*. *January*.
49. Sawynok, J. (2005). Topical Analgesics in Neuropathic Pain. *Current Pharmaceutical Design*, *11*(23), 2995–3004. https://doi.org/10.2174/1381612054865019
50. Scholz, A. (2002). Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. *British Journal of Anaesthesia*, *89*(1), 52–61. https://doi.org/10.1093/bja/aef163
51. Schug, S. A., Robert Garrett, W., & Gillespie, G. (2003). Opioid and non-opioid analgesics. *Best Practice and Research: Clinical Anaesthesiology*, *17*(1), 91–110. https://doi.org/10.1053/bean.2003.0267
52. Seyfried, O., & Hester, J. (2012). Opioids and endocrine dysfunction. *British Journal of Pain*, *6*(1), 17–24. https://doi.org/10.1177/2049463712438299
53. Smith, H. S. (2008). Variations in opioid responsiveness. *Pain Physician*, *11*(2), 237–248. https://doi.org/10.36076/ppj.2008/11/237
54. Stylianou, N., Buchan, I., & Dunn, K. W. (2015). A review of the international Burn Injury Database (iBID) for England and Wales: descriptive analysis of burn injuries 2003-2011. *BMJ Open*, *5*(2). https://doi.org/10.1136/BMJOPEN-2014-006184
55. Tournaire, M., & Theau-Yonneau, A. (2007). Complementary and alternative approaches to pain relief during labor. *Evidence-Based Complementary and Alternative Medicine*, *4*(4), 409–417. https://doi.org/10.1093/ecam/nem012
56. Trescot, A. M., Datta, S., Lee, M., & Hans, H. (2008). Opioid pharmacology. *Pain Physician*, *11*(SPEC. ISS. 2), 133–154. https://doi.org/10.36076/ppj.2008/11/s133
57. Trescot, A. M., Helm, S., Hansen, H., Benyamin, R., Glaser, S. E., Adlaka, R., Patel, S., Manchikanti, L., Datta, S., Sehgal, N., Colson, J., Jordan, A., & Lee, M. (2008). Opioids in the management of chronic non-cancer pain: An update of American

Society of the Interventional Pain Physicians' (ASIPP) guidelines. *Pain Physician*, *11*(SPEC. ISS. 2), 5–62. https://doi.org/10.36076/ppj.2008/11/s5

58. Valentino, R. J., & Volkow, N. D. (2018). Untangling the complexity of opioid receptor function. *Neuropsychopharmacology*, *43*(13), 2514–2520. https://doi.org/10.1038/s41386-018-0225-3
59. Velásquez, G., Cruz, L. A., & Espinoza, M. (2014). Ketoprofen Is More Effective Than Diclofenac After Oral Surgery When Used as a Preemptive Analgesic: A Pilot Study. *Journal of Oral & Facial Pain and Headache*, *28*(2), 153–158. https://doi.org/10.11607/ofph.1200
60. Vyvey, M. (2010). Steroids as pain relief adjuvants. *Canadian Family Physician Medecin de Famille Canadien*, *56*(12), 1295–1297, e415. http://www.ncbi.nlm.nih.gov/pubmed/21156893%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3001922
61. Wallace, M. S., & Papp, A. (2017). Opioid withdrawal. *Challenging Cases and Complication Management in Pain Medicine*, 15–20. https://doi.org/10.1007/978-3-319-60072-7_3
62. Walsh, S. L., Nuzzo, P. A., Lofwall, M. R., & Holtman, J. R. (2008). The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. *Drug and Alcohol Dependence*, *98*(3), 191–202. https://doi.org/10.1016/j.drugalcdep.2008.05.007
63. Webster, L. R., & Webster, R. M. (2005). Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. *Pain Medicine*, *6*(6), 432–442. https://doi.org/10.1111/j.1526-4637.2005.00072.x
64. Yam, M. F., Loh, Y. C., Tan, C. S., Adam, S. K., Manan, N. A., & Basir, R. (2018). General pathways of pain sensation and the major neurotransmitters involved in pain regulation. *International Journal of Molecular Sciences*, *19*(8). https://doi.org/10.3390/ijms19082164
65. Yanagidate, F., & Strichartz, G. R. (2007). Local anesthetics. *Handbook of Experimental Pharmacology*, *177*, 95–127. https://doi.org/10.1007/978-3-540-33823-9_4
66. Yu, K., Niu, X., & He, B. (2020). Neuromodulation Management of Chronic Neuropathic Pain in the Central Nervous System. *Advanced Functional Materials*, *30*(37), 1–19. https://doi.org/10.1002/adfm.201908999
67. Ziccardi, P., Nappo, F., Giugliano, G., Esposito, K., Marfella, R., Cioffi, M., D'Andrea, F., Molinari, A. M., & Giugliano, D. (2002). Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. *Circulation*, *105*(7), 804–809. https://doi.org/10.1161/hc0702.104279

*Corresponding Author: **Ashvini Mansing Deshmukh**